You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Swedish firms plans to launch clinical performance studies in support of getting CE marking for its QuickMIC system.
Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the US.
The assay will be available on the Vitros 3600 Immunodiagnostic System, Vitros 5600 and Vitros XT 7600 Integrated Systems, and Vitros ECi/ECiQ Systems.
The method uses nanopore sequencing to analyze short cell-free DNA fragments from blood, providing results in as little as six hours.
GenMark announced on Monday that it has begun shipping its first research-use-only tests for the novel coronavirus and intends to seek emergency use authorization.
More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.
As part of the new sales process the firm launched a return-on-investment tool that adapts data from existing customers to predict potential outcomes.
The firm placed 137 commercially contracted instruments in the quarter and 304 in the full year 2019.
Leadership aims to lower cost of goods and real estate footprint, while driving test utilization by targeting clinicians.
The firm placed 45 of its T2Dx diagnostics instruments in 2019, but plans to reduce that number in 2020 to focus on instrument utilization.